이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

BridgeBio Pharma 관리

관리 기준 확인 2/4

BridgeBio Pharma's CEO는 Neil Kumar, Apr2015 에 임명되었습니다 의 임기는 9.17 년입니다. 총 연간 보상은 $ 12.16M, 6.1% 로 구성됩니다. 6.1% 급여 및 93.9% 보너스(회사 주식 및 옵션 포함). 는 $ 190.67M 가치에 해당하는 회사 주식의 3.69% 직접 소유합니다. 190.67M. 경영진과 이사회의 평균 재임 기간은 각각 5.4 년과 4.4 년입니다.

주요 정보

Neil Kumar

최고 경영자

US$12.2m

총 보상

CEO 급여 비율	6.1%
CEO 임기	9.4yrs
CEO 소유권	3.7%
경영진 평균 재임 기간	5.2yrs
이사회 평균 재임 기간	4.7yrs

최근 관리 업데이트

Recent updates

Revenues Not Telling The Story For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Sep 24

BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis

Aug 31

BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon

Aug 17

BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

Jun 10

BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

Jul 02

New Forecasts: Here's What Analysts Think The Future Holds For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

May 09

Time To Worry? Analysts Just Downgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Outlook

Feb 28

Analysts Just Made A Major Revision To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts

Jan 09

BridgeBio stock rises as BBP-398, Lumakras combo for lung cancer gets FDA fast track status

Oct 11

BridgeBio, Sentynl's Nulibry for rare disorder in children gets approval in EU

Sep 20

BridgeBio Pharma: Down But Not Out

Aug 31

BridgeBio starts dosing in phase 1 trial of BBP-671 for metabolic disorders

Aug 18

CEO 보상 분석

Neil Kumar 의 보수는 BridgeBio Pharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$454m
Mar 31 2024	n/a	n/a	-US$538m
Dec 31 2023	US$12m	US$742k	-US$643m
Sep 30 2023	n/a	n/a	-US$613m
Jun 30 2023	n/a	n/a	-US$573m
Mar 31 2023	n/a	n/a	-US$425m
Dec 31 2022	US$7m	US$1m	-US$481m
Sep 30 2022	n/a	n/a	-US$491m
Jun 30 2022	n/a	n/a	-US$509m
Mar 31 2022	n/a	n/a	-US$596m
Dec 31 2021	US$26m	US$725k	-US$563m
Sep 30 2021	n/a	n/a	-US$535m
Jun 30 2021	n/a	n/a	-US$495m
Mar 31 2021	n/a	n/a	-US$520m
Dec 31 2020	US$10m	US$550k	-US$449m
Sep 30 2020	n/a	n/a	-US$402m
Jun 30 2020	n/a	n/a	-US$346m
Mar 31 2020	n/a	n/a	-US$291m
Dec 31 2019	US$26m	US$503k	-US$261m
Sep 30 2019	n/a	n/a	-US$226m
Jun 30 2019	n/a	n/a	-US$197m
Mar 31 2019	n/a	n/a	-US$155m
Dec 31 2018	US$450k	US$450k	-US$131m

보상 대 시장: Neil 의 총 보상 ($USD 12.16M )은 US 시장( $USD 8.45M ).

보상과 수익: 회사가 수익성이 없는 동안 Neil 의 보상이 증가했습니다.

CEO

Neil Kumar (45 yo)

9.4yrs

테뉴어

US$12,158,626

보상

Dr. Neil Kumar, Ph D., has been Director of Lianbio since October 2019. He is a Co-Founder of BridgeBio Pharma, Inc. and serves as its Chief Executive Officer and Director since April 2015.He served as Pr...

리더십 팀

이름	위치	테뉴어	보상	소유권
Neil Kumar	Co-Founder	9.4yrs	US$12.16m	3.67% $ 172.2m
Charles Homcy	Co-Founder	no data	US$1.11m	0.65% $ 30.7m
Frank McCormick	Co-Founder	no data	US$1.74m	0.59% $ 27.4m
Brian Stephenson	CFO & Secretary	5.9yrs	US$6.65m	0.045% $ 2.1m
Richard Scheller	Chairman of Research & Development	5.7yrs	US$2.01m	데이터 없음
Thomas Trimarchi	President & COO	less than a year	데이터 없음	0.20% $ 9.4m
Uma Sinha	Chief Scientific Officer	8.4yrs	US$2.75m	데이터 없음
Grace Rauh	Vice President of Communications	no data	데이터 없음	데이터 없음
Eli Wallace	Chief Scientific Officer of Oncology	4.8yrs	데이터 없음	데이터 없음
Eric David	Chief Executive Officer of Gene Therapy	no data	데이터 없음	데이터 없음
Matthew Outten	Chief Commercial Officer	3.3yrs	데이터 없음	데이터 없음
Adora Ndu	Chief Regulatory Affairs Officer	2.7yrs	데이터 없음	데이터 없음

5.2yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: BBIO 의 관리팀은 노련하고 경험 (평균 재직 기간 5.4 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Neil Kumar	Co-Founder	9.4yrs	US$12.16m	3.67% $ 172.2m
Charles Homcy	Co-Founder	5.8yrs	US$1.11m	0.65% $ 30.7m
Frank McCormick	Co-Founder	less than a year	US$1.74m	0.59% $ 27.4m
Fred Hassan	Independent Director	3.1yrs	US$600.00k	0.010% $ 481.1k
Ronald Daniels	Independent Director	4.6yrs	US$600.00k	0.0055% $ 259.3k
Eric Aguiar	Independent Director	5.5yrs	US$600.00k	0% $ 0
Randal Scott	Independent Director	4.3yrs	US$600.00k	0.0048% $ 224.6k
Ali Satvat	Independent Director	8.5yrs	US$600.00k	0% $ 0
James Momtazee	Director	8.5yrs	US$600.00k	0.047% $ 2.2m
Jennifer Cook	Director	4.8yrs	US$600.00k	0.0038% $ 178.2k
Wen-Chaun Lo	Independent Director	4.3yrs	US$600.00k	0.13% $ 6.3m
Andrea Ellis	Independent Director	3.1yrs	US$600.00k	0.0064% $ 299.2k

4.7yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 이사회: BBIO 의 이사회는 경험(평균 재직 기간 4.4 년)으로 간주됩니다.

BridgeBio Pharma 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Co-Founder notifies of intention to sell stock

BridgeBio Pharma, Inc. Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

CFO & Secretary exercised options and sold US$433k worth of stock

BridgeBio Pharma, Inc., Annual General Meeting, Jun 21, 2024

Co-Founder exercised options and sold US$1.8m worth of stock

Co-Founder notifies of intention to sell stock

Recent updates

Revenues Not Telling The Story For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis

BridgeBio Pharma, Inc. Presents Additional Data from an Analysis of its Phase 3 ATTRibute-CM and Open-Label Extension Study of Acoramidis in ATTR-CM at the European Society of Cardiology 2024

Co-Founder notifies of intention to sell stock

BridgeBio Pharma, Inc. and QED Therapeutics Announce the Launch of the Initial Phase of MyAchonJourney

BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon

Consensus EPS estimates upgraded to US$2.19 loss, revenue downgraded

New major risk - Financial position

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

BridgeBio Pharma, Inc. Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

BridgeBio Pharma, Inc. Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

BridgeBio Pharma, Inc. Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)

Consensus revenue estimates increase by 11%

CFO & Secretary exercised options and sold US$433k worth of stock

Consensus revenue estimates increase by 138%

Consensus revenue estimates increase by 162%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

BridgeBio Pharma, Inc., Annual General Meeting, Jun 21, 2024

BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement

Consensus revenue estimates increase by 83%

BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million.

Consensus revenue estimates increase by 44%

BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million.

BridgeBio Pharma, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates increase by 81%, EPS downgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder exercised options and sold US$1.8m worth of stock

New major risk - Financial position

BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy

BridgeBio Pharma, Inc. Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

Consensus revenue estimates fall by 25%

BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck

BridgeBio Pharma, Inc. Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy in the New England Journal of Medicine

Co-Founder notifies of intention to sell stock

BridgeBio Pharma, Inc. Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia

Now 22% undervalued after recent price drop

Co-Founder notifies of intention to sell stock

BridgeBio Pharma, Inc. Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Consensus EPS estimates fall by 11%, revenue upgraded

Now 22% undervalued after recent price drop

Estimating The Intrinsic Value Of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 13%

BridgeBio Pharma, Inc. Shares Positive Long-Term Data from an Ongoing Phase 2 Study, Which Support the Potential Use of Glycosylated Alpha-dystroglycan (DG) Levels as a Surrogate Endpoint in Limb-Girdle Muscular Dystrophy Type 2I/R9

BridgeBio Pharma, Inc. announced that it expects to receive $250.003806 million in funding from Qatar Investment Authority and other investors

Bridgebio Pharma Announces Positive Feedback from the U.S. Fda and Eu Ema on the Regulatory Path for A Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia

BridgeBio Pharma, Inc. Presents Detailed Positive Results from Phase 3 Attribute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) At European Society of Cardiology Congress 2023

Co-Founder notifies of intention to sell stock

New minor risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Bridgebio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-Girdle Muscular Dystrophy Type 2I (Lgmd2i/R9) Based on Glycosylated Alpha-Dystroglycan (Dg) Levels and Announces First Patient Dosed in Fortify Phase 3 Study

Bridgebio Announces Consistently Positive Results from Phase 3 Attribute-Cm Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy

Price target increased by 20% to US$33.90

BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

BridgeBio Pharma, Inc. Presents Updated Six Month Results from Its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia

CFO & Secretary exercised options and sold US$632k worth of stock

Price target increased by 8.3% to US$28.40

New Forecasts: Here's What Analysts Think The Future Holds For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Co-Founder notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder notifies of intention to sell stock

Consensus revenue estimates increase by 105%

Price target increased by 8.6% to US$23.90

Consensus revenue estimates decrease by 53%, EPS upgraded

Time To Worry? Analysts Just Downgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Outlook

Key Executive notifies of intention to sell stock

Full year 2022 earnings released: US$3.26 loss per share (vs US$3.90 loss in FY 2021)